A few examples of "how" developmental cancer antibody companies...

A few examples of "how" developmental cancer antibody companies make $$$ (from Patrys recent corporate overview). The "when" - well this will be dependent on the perceived quality of the asset (antibody) and/or the extent to which "de-risking" of the asset has occurred.

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
0	{colgroup}
1	{col}{/col}{col}{/col}{col}{/col}{col}{/col}{col}{/col}{col}{/col}
2	{/colgroup}
3	Date	Tech	Seller	Buyer	Total (USD)	Up Front (USD)
4	Feb-14	Nanobody platform	Ablynx	Merck	6.5B	27 M
5	Jan-15	Checkpoint regulators: GITR, OX40, LAG-3 and TIM-3	Agenus	Incyte	410M	60M
6	Aug-15	Anti-GDF15 MAb	Aveo Oncology	Novartis	326M	15M
7	Oct-15	Anti-TGF-beta MAb	Xoma	Novartis	480M	37M
8	Jan-16	Cell-penetrating alphabodies*	Complix	Merck	280M	N/A
9	May-16	Bi-specific Ab, alternative to CAR-T	Macro-Genics	Janssen	740M	75M
10	Jul-16	4 early stage Abs	Jounce	Celgene	2.6B	261M
11	Jun-17	Intracellular delivery platform	Feldan/Elasmogen	Amgen	N/A	N/A
12	Nov-17	Bi-specific antibody platform	Zymeworks	J&J	332M	50M
13	April-18	Bi-specific antibody platform	Compugen	Astra Zeneca	210M	10M
14	April-18	Checkpoint inhibitor: OSE-172 a SIRP alpha antagonist	OSE Immunotherapeutics	Boehringer Ingelheim	1.4B	18.4M
15	*Collaboration expanded in 2017